HLP003, or HLP-003, also known as deuterated psilocybin analogue and formerly as CYB003, is a serotonergic psychedelic related to psilocybin which is under development for the treatment of major depressive disorder, alcoholism, and other psychiatric disorders. It is taken orally. The drug is a tryptamine derivative and is a deuterated analogue of psilocybin and psilocin.

Interactions

Pharmacology

The pharmacodynamic profile of HLP003, including its interactions with serotonin receptors and its effects in animals, is similar to that of psilocin. As with psilocin, HLP003 is a potent agonist of the serotonin 5-HT2A receptor and produces psychedelic-like effects in animals. However, it was developed to have improved pharmacokinetic properties compared to psilocybin, including reduced variability in circulating levels, a faster onset of action, and a shorter duration.

In humans, HLP003 has been reported to have 2.2-fold higher peak levels and 3.5-fold higher area-under-the-curve (AUC) levels than psilocybin at equivalent doses. It is said to have a rapid onset of less than 15minutes and a duration of 4 to 6hours.

Chemistry

Deupsilocin (INNTooltip International Nonproprietary Name; d10-psilocin) structure.

The exact chemical structure of HLP003 (i.e., which specific hydrogen atoms have been deuterated) does not yet seem to have been disclosed. However, an INNTooltip International Nonproprietary Name of deupsilocin for a deuterated form of psilocin called d10-psilocin (decadeuteropsilocin) with CAS number 1435934-64-7 was proposed in 2023 and recommended in 2024. This deuterated analogue of psilocin has been patented by Helus Pharma (formerly Cybin) as well as by Lennham Pharmaceuticals. Helus Pharma has also patented other deuterated psilocin analogues. Other deuterated drugs related to HLP003 or deupsilocin/d10-psilocin include the deuterated DMT analogues HLP004 (CYB004) and SPL028 and the deuterated phenethylamine HLP005 (CYB005).

Research

In 2024, HLP003 received a breakthrough therapy designation from the U.S. FDA and was in phase 3 clinical trials for major depressive disorder and is in the preclinical stage of development for alcoholism and other psychiatric disorders. Two phase 3 clinical trials for major depressive disorder are being initiated in November 2024 and February 2025. The drug is under development by Helus Pharma (formerly Cybin).

See also

External links